Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic Populations
- 1 July 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (7) , 2329-2336
- https://doi.org/10.1128/aac.00185-07
Abstract
Isoniazid, administered as part of combination antituberculosis therapy, is responsible for most of the early bactericidal activity (EBA) of the regimen. However, the emergence of Mycobacterium tuberculosis resistance to isoniazid is a major problem. We examined the relationship between isoniazid exposure and M. tuberculosis microbial kill, as well as the emergence of resistance, in our in vitro pharmacodynamic model of tuberculosis. Since single-nucleotide polymorphisms of the N -acetyltransferase-2 gene lead to two different clearances of isoniazid from serum in patients, we simulated the isoniazid concentration-time profiles encountered in both slow and fast acetylators. Both microbial kill and the emergence of resistance during monotherapy were associated with the ratio of the area under the isoniazid concentration-time curve from 0 to 24 h (AUC 0-24 ) to the isoniazid MIC. The time in mutant selection window hypothesis was rejected. Next, we utilized the in vitro relationship between the isoniazid AUC 0-24 /MIC ratio and microbial kill, the distributions of isoniazid clearance in populations with different percentages of slow and fast acetylators, and the distribution of isoniazid MICs for isonazid-susceptible M. tuberculosis clinical isolates in Monte Carlo simulations to calculate the EBA expected for ∼10,000 patients treated with 300 mg of isoniazid. For those patient populations in which the proportion of fast acetylators and the isoniazid MICs were high, the average EBA of the standard dose was ∼0.3 log 10 CFU/ml/day and was thus suboptimal. Our approach, which utilizes preclinical pharmacodynamics and the genetically determined multimodal distributions of serum clearances, is a preclinical tool that may be able to predict the EBAs of various doses of new antituberculosis drugs.Keywords
This publication has 42 references indexed in Scilit:
- The Relationship between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: a New Paradigm for Optimizing Pharmacodynamics To Counterselect ResistanceAntimicrobial Agents and Chemotherapy, 2007
- Isoniazid’s Bactericidal Activity Ceases because of the Emergence of Resistance, Not Depletion ofMycobacterium tuberculosisin the Log Phase of GrowthThe Journal of Infectious Diseases, 2007
- The Crisis of Resistance: Identifying Drug Exposures to Suppress Amplification of Resistant Mutant SubpopulationsClinical Infectious Diseases, 2006
- Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical ImplicationsThe Oncologist, 2006
- Pharmacodynamic Evidence that Ciprofloxacin Failure against Tuberculosis Is Not Due to Poor Microbial Kill but to Rapid Emergence of ResistanceAntimicrobial Agents and Chemotherapy, 2005
- The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of IsoniazidClinical Infectious Diseases, 2004
- Selection of a Moxifloxacin Dose That Suppresses Drug Resistance inMycobacterium tuberculosis,by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical ModelingThe Journal of Infectious Diseases, 2004
- Mutations in katG , inhA , and ahpC Genes of Brazilian Isoniazid-Resistant Isolates of Mycobacterium tuberculosisJournal of Clinical Microbiology, 2003
- Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidencecclm, 2003
- Arylamine N-acetyltransferase (NAT2) genotypes in AfricansPharmacogenetics, 2003